tacrolimus + cyclosporine A

Tacrolimus + cyclosporine A refers to the immunosuppressive regimen evaluated in a clinical trial (NCT06104111) led by Wei Gao, which focuses on the efficacy and safety of withdrawing these agents in pediatric liver transplant recipients. Both tacrolimus and cyclosporine A are potent calcineurin inhibitors used to prevent graft rejection. Tacrolimus acts by binding to the intracellular protein FKBP12, while cyclosporine A binds to cyclophilin A; both resulting complexes inhibit the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NFAT), thereby blocking the transcription of interleukin-2 (IL-2) and other cytokines essential for T-lymphocyte activation. The specific study investigates the feasibility of inducing immune tolerance by gradually tapering these medications to identify biomarkers that predict successful withdrawal without graft rejection.

Other names

Tacrolimus or Cyclosporine Atacrolimus + cyclosporine A-Wei Gao-liver transplantationIS withdrawal protocolImmunosuppressive Withdrawal in Pediatric Liver Transplant